Research programme: somatropin mimetics - Celera Genomics/Pfizer

Drug Profile

Research programme: somatropin mimetics - Celera Genomics/Pfizer

Alternative Names: Growth hormone mimetics research programme - Celera Genomics/Pfizer; Somatropin mimetics research programme - Celera Genomics/Pfizer

Latest Information Update: 19 Jan 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celera Genomics Group; Pfizer
  • Class
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Growth disorders

Most Recent Events

  • 19 Jan 2005 No development reported - Preclinical for Growth disorders in USA (unspecified route)
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 04 Dec 2001 Axys Pharmaceuticals has been acquired by Celera Genomics Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top